Provided are tricyclic compounds of the general formula (I), wherein the variables are as described in the specification. Preferred compounds comprise a tricyclic ring system containing a furan ring and an oxazepine ring. The compounds inhibit the non-structural 5B (NS5B) protein of hepatitis C virus (HCV).